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Abstract 
Study question: What is the optimal management of women with premature ovarian insufficiency based on 
the best available evidence in the literature? 
 
Summary answer: The guideline development group formulated 99 recommendations answering 31 key 
questions on the diagnosis and treatment of women with premature ovarian insufficiency.   
What is known already: NA 
Study design, size, duration: This guideline was produced by a multidisciplinary group of experts in the field 
using the methodology of the Manual for ESHRE Guideline Development, including a thorough systematic 
search of the literature, quality assessment of the included papers up to September 2014 and consensus 
within the guideline group on all recommendations. The guideline development group included a patient 
representative to ensure input from women with POI. After finalisation of the draft, ESHRE members and 
professional organisations were asked to review the guideline.  
Participants/materials, setting, methods: NA 
Main results and the role of chance: The guideline provides 17 recommendations on diagnosis and 
assessment of POI and 46 recommendations on the different sequelae of POI and their consequences for 
monitoring and treatment. Furthermore, 24 recommendations were formulated on hormone replacement 
therapy in women with POI, and 2 on alternative and complementary treatment. A chapter on puberty 
induction resulted in 5 recommendations.   
Limitations, reasons for caution:  The main limitation of the guideline is that due to the lack of data, many of 
the recommendations are based on expert opinion, or indirect evidence from studies on postmenopausal 
women or women with Turner Syndrome, were possible.   
Wider implications of the findings: Despite the limitations, the guideline group is confident that this 
document will be able to guide health care professionals in providing the best practice for managing women 
with POI given current evidence. Furthermore, the guideline group has formulated research recommendations 
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on the gaps in knowledge identified in the literature searches, in an attempt to stimulate research on the key 
issues in POI.   
Study funding/competing interest(s): The guideline was developed and funded by ESHRE, covering expenses 
associated with the guideline meetings, with the literature searches and with the implementation of the 
guideline. The guideline group members did not receive payment.  All guideline group members disclosed 
conflicts of interest.  
Trial registration number: NA 
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Introduction 
This ESHRE guideline on the management of women with premature ovarian insufficiency offers best practice 
advice on the care of women with premature ovarian insufficiency, both primary and secondary. The patient 
population comprises women younger than 40 years (which includes Turner Syndrome patients) and women 
older than 40 years, but with disease onset before 40.   
Furthermore, this clinical guideline provides recommendations on the initial assessment and management of 
women with premature ovarian insufficiency. The initial assessment includes diagnosis, assessment of 
causation, and basic assessment. The management includes hormonal treatment. Since POI has consequences 
for health apart from gynaecological issues, these are also described. Consequences of POI and treatment 
options are included in the following domains: fertility and contraception, bone health, cardiovascular issues, 
psychosexual function, psychological function, and neurological function.  
Other topics discussed are puberty induction, life expectancy, and implications for relatives of women with 
POI. 
This guideline is limited to POI and does not apply to women with low ovarian reserve. 
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Methods 1 
The guideline was developed according to a well-documented methodology, universal to ESHRE guidelines 2 
(Vermeulen, et al., 2014).   3 
In short, 31 key questions were formulated by the guideline group and structured in PICO format (Patient, 4 
Intervention, Comparison, Outcome). For each question we searched the databases (PUBMED/MEDLINE , 5 
Cochrane library, PsycInfo) from inception to 1 April 2014. The literature searches were limited to studies 6 
written in English.  Based on the evidence, and after constructing evidence tables and quality assessment, draft 7 
recommendations were written by the assigned expert guideline group member. Two 2-day meetings were 8 
organised to discuss the evidence and recommendations and to reach consensus on the final formulation of 9 
the recommendations.  10 
For each recommendation, a grade (A-D) was assigned based on the strength of the supporting evidence 11 
(scored from 1++ to 4). In case of absence of evidence, the Guideline Development Group (GDG) could decide 12 
on writing good practice points (GPP), based on clinical expertise (see table 1).  13 
After finalisation of the guideline draft, an invitation to review was published on the ESHRE website. In 14 
addition, an invitation to review was sent to members of the ESHRE special interest group Reproductive 15 
Endocrinology (n=6000) and to professional organisations on human reproduction, gynaecology, 16 
endocrinology and menopause (n=79). Three hundred ninety-eight comments from 34 reviewers were 17 
processed by the methodological expert (NV) and the chair of the GDG (LW) either by adapting the content of 18 
the guideline and/or by replying to the reviewer. The review process was summarized in the review report, 19 
published on the ESHRE website. 20 
The guideline will be considered for update 4 years after publication, with an intermediate assessment 21 
of the need for updating 2 years after publication.  22 
23 
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Key questions and recommendations 24 
The current document summarizes the key questions and the recommendations for clinical practice. Further 25 
background information and the supporting evidence for each recommendation can be found in the full 26 
version of the guideline available at http://www.eshre.eu/Guidelines-and-Legal/Guidelines  27 
What should this condition be called?  28 
Primary ovarian insufficiency was first described in 1942 and has, since then, been described with different 29 
names and definitions (Albright, et al., 1942).  30 
The term “premature ovarian insufficiency” should be used to describe this condition in 
research and clinical practice. 
GPP 
 31 
How should POI be defined? 32 
Premature ovarian insufficiency is a clinical syndrome defined by loss of ovarian activity before the age of 40.  33 
POI is characterised by menstrual disturbance (amenorrhea or oligomenorrhea) with raised gonadotropins and 34 
low estradiol. 35 
What is the prevalence of Premature Ovarian Insufficiency in the general population? 36 
The prevalence of POI is approximately 1%. Population characteristics such as ethnicity may affect the 37 
prevalence.  38 
In view of the long-term health consequences of POI, efforts should be made to reduce the incidence of POI. 39 
Modifiable factors may include: (1) gynaecological surgical practice, (2) lifestyle – smoking, (3) modified 40 
treatment regimens for malignant and chronic diseases.  41 
 42 
DIAGNOSIS OF POI  43 
Summary of diagnostic workup in table 2. 44 
What are the symptoms of Premature Ovarian Insufficiency? 45 
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Clinicians should enquire about symptoms of estrogen deficiency in women presenting with 
oligomenorrhea or amenorrhea. 
GPP 
POI needs to be excluded in women with amenorrhea/oligomenorrhea or estrogen-deficiency 
symptoms below the age of 40 years. 
GPP 
  46 
What investigations should be performed for diagnosis of premature ovarian insufficiency?  47 
The diagnosis Premature Ovarian Insufficiency is based on the presence of menstrual disturbance and 48 
biochemical confirmation. 49 
Although proper diagnostic accuracy in POI is lacking, the GDG recommends the following 
diagnostic criteria: (1) oligo/amenorrhea for at least 4 months, and (2) an elevated FSH level > 
25 IU/l on two occasions > 4 weeks apart. 
GPP 
  50 
What are the known causes of POI and how should they be investigated?  51 
Chromosomal analysis should be performed in all women with non-iatrogenic Premature 
Ovarian Insufficiency (Bachelot, et al., 2009, Jiao, et al., 2012, Kalantari, et al., 2013, Rocha, et 
al., 2011). 
C 
Gonadectomy should be recommended for all women with detectable Y chromosomal 
material (Rocha, et al., 2011). 
C 
Fragile-X premutation testing is indicated in POI women (Bachelot, et al., 2009, Genetics 
Committee of the Society of Obstetricians and Gynaecologists of Canada, et al., 2008). 
B 
The implications of the fragile-X premutation should be discussed before the test is performed. GPP 
 52 
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Autosomal genetic testing is not at present indicated in women with POI, unless there is 
evidence suggesting a specific mutation (e.g. BPES). 
GPP 
Screening for 21OH-Ab (or alternatively adrenocortical antibodies (ACA)) should be considered 
in women with POI of unknown cause or if an immune disorder is suspected. 
Refer POI patients with a positive 21OH-Ab/ACA test to an endocrinologist for testing of 
adrenal function and to rule out Addison’s disease (Bakalov, et al., 2002, Chen, et al., 1996, Dal 
Pra, et al., 2003, Husebye and Lovas, 2009) 
C 
 Screening for thyroid (TPO-Ab) antibodies should be performed in women with POI of 
unknown cause or if an immune disorder is suspected. 
In patients with a positive TPO-Ab test, thyroid stimulating hormone (TSH) should be measured 
every year (Goswami, et al., 2006, Hollowell, et al., 2002, Kim, et al., 1997).  
C 
 There is insufficient evidence to recommend routinely screening POI women for diabetes 
(Kim, et al., 1997). 
D 
There is no indication for infection screening in women with POI (Kokcu, 2010). D 
The possibility of POI being a consequence of a medical or surgical intervention should be 
discussed with women as part of the consenting process for that treatment. 
GPP 
Although no causal relation has been proved for cigarette smoking and POI, there is a relation 
to early menopause. Therefore, women who are prone to POI should be advised to stop 
smoking.  
GPP 
 53 
In a significant number of women with POI, the cause is not identified and these women are described as 54 
having unexplained or idiopathic POI. 55 
How often should tests for autoantibodies be repeated?  56 
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If 21OH-Ab/ACA and TPO-Ab are negative in women with POI, there is no indication for re-
testing later in life, unless signs or symptoms of these endocrine diseases develop (Betterle, et 
al., 1997). 
C 
 57 
What are the implications for relatives of women with POI? 58 
 Relatives of women with the fragile-X premutation should be offered genetic counselling and 
testing (Finucane, et al., 2012, Genetics Committee of the Society of Obstetricians and 
Gynaecologists of Canada, et al., 2008). 
B 
Relatives of women with non-iatrogenic premature ovarian insufficiency who are concerned 
about their risk for developing POI should be informed that: (1) currently  there is no proven 
predictive test to identify women that will develop POI, unless a mutation known to be related 
to POI was detected, (2) there are no established POI preventing measures, (3) fertility 
preservation appears as a promising option, although studies are lacking, and (4) their 
potential risk of earlier menopause should be taken into account when planning a family. 
GPP 
 59 
SEQUELAE OF POI 60 
What are the consequences of POI for life expectancy? 61 
Untreated POI is associated with reduced life expectancy, largely due to cardiovascular disease 
(Amagai, et al., 2006, Hong, et al., 2007, Ossewaarde, et al., 2005, Rocca, et al., 2006, Wu, et 
al., 2014).  
C 
Women with POI should be advised on how to reduce cardiovascular risk factors by not 
smoking, taking regular exercise, and maintaining a healthy weight.  
GPP 
 62 
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What are the consequences of POI for fertility? 63 
Women with POI should be informed that there is a small chance of spontaneous pregnancy. GPP 
Women with POI should be advised to use contraception if they wish to avoid pregnancy. GPP 
 64 
What fertility interventions are effective? 65 
Inform women with POI that there are no interventions that have been reliably shown to 
increase ovarian activity and natural conception rates (van Kasteren and Schoemaker, 1999). 
A 
Oocyte donation is an established option for fertility in women with POI (Oyesanya, et al., 
2009, Sauer, et al., 1994, Sung, et al., 1997, Templeton, et al., 1996). 
C 
Inform women considering oocyte donation from sisters that this carries a higher risk of cycle 
cancellation  (Sung, et al., 1997) 
C 
In women with established POI, the opportunity for fertility preservation is missed.  GPP 
 66 
What are the obstetric risks associated with POI? 67 
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Women should be reassured that spontaneous pregnancies after idiopathic POI or most forms 
of chemotherapy do not show any higher obstetric or neonatal risk than in the general 
population (Scottish Intercollegiate Guidelines Network (SIGN), 2013, Signorello, et al., 2012). 
B 
Oocyte donation pregnancies are high risk and should be managed in an appropriate obstetric 
unit. Women and their partners should be encouraged to disclose the origin of their pregnancy 
with their obstetric team (Abdalla, et al., 1998, Nelson and Lawlor, 2011, Pados, et al., 1994, 
Soderstrom-Anttila, et al., 1998, Stoop, et al., 2012). 
C 
Antenatal aneuploidy screening should be based on the age of the oocyte donor (Bowman and 
Saunders, 1994, Donnenfeld, et al., 2002).  
C 
Pregnancies in women who have received radiation to the uterus are at high risk of obstetric 
complications and should be managed in an appropriate obstetric unit (Bath, et al., 1999, 
Larsen, et al., 2004, Scottish Intercollegiate Guidelines Network (SIGN), 2013, Signorello, et al., 
2010, Wo and Viswanathan, 2009). 
C 
Pregnancies in women with Turner Syndrome are at very high risk of obstetric and non-
obstetric complications and should be managed in an appropriate obstetric unit with 
cardiologist involvement (Bryman, et al., 2011, Hadnott, et al., 2011, Hagman, et al., 2013, 
Karnis, 2012). 
D 
A cardiologist should be involved in care of pregnant women who have received anthracyclines 
and/or cardiac irradiation (Mulrooney, et al., 2009, Scottish Intercollegiate Guidelines Network 
(SIGN), 2013). 
D 
 68 
How should fitness for pregnancy be assessed in women with POI? 69 
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Women presenting for oocyte donation who are suspected of having POI should be fully 
investigated prior to oocyte donation, including thyroid and adrenal function as well as 
karyotype (Abdalla, et al., 1998). 
C 
Women previously exposed to anthracyclines, high dose cyclophosphamide or mediastinal 
irradiation should have an echocardiogram prior to pregnancy, and referral to a cardiologist if 
indicated (Altena, et al., 2012, Bar, et al., 2003, Felker, et al., 2000, Gorton, et al., 2000, van 
Dalen, et al., 2006). . 
D 
Women with Turner Syndrome should be assessed by a cardiologist with a specialist interest in 
adult congenital heart disease and should have a general medical and endocrine examination. 
GPP 
Women with POI should have their blood pressure, renal function, and thyroid function 
assessed prior to pregnancy (Haddow, et al., 1999). 
C 
Pregnancy in some women can be of such high risk that clinicians may consider oocyte 
donation to be life threatening and therefore inappropriate. 
GPP 
 70 
What are the consequences of POI for bone health?  71 
POI is associated with reduced bone mineral density (BMD) (Bachelot, et al., 2009, Bakalov, et 
al., 2003, Castaneda, et al., 1997, Conway, et al., 1996, Freriks, et al., 2011, Hadjidakis, et al., 
1999, Han, et al., 2008, Michala, et al., 2008, Park, et al., 1999, Popat, et al., 2009, Ratcliffe, et 
al., 1992). 
B 
Reduced BMD is very likely to indicate that POI is associated with an increased risk of fracture 
later in life, although this has not been adequately demonstrated. 
GPP 
 72 
What are the treatment options for bone protection and improvement? 73 
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Women should maintain a healthy lifestyle, involving weight-bearing exercise, avoidance of 
smoking, and maintenance of normal body weight to optimize bone health. 
GPP 
A balanced diet will contain the recommended intake of calcium and vitamin D. Dietary 
supplementation may be required in women with inadequate vitamin D status and/or calcium 
intake, and may be of value in women with low BMD (Bours, et al., 2011, Challoumas, et al., 
2013). 
C 
Estrogen replacement is recommended to maintain bone health and prevent osteoporosis; it is 
plausible that it will reduce the risk of fracture (Kanis, et al., 2013, Lindsay, et al., 1980, Prior, 
et al., 1997). 
C 
The combined oral contraceptive pill may be appropriate for some women but effects on BMD 
are less favourable (Crofton, et al., 2010)  
C 
Other pharmacological treatments, including bisphosphonates, should only be considered with 
advice from an osteoporosis specialist. Particular caution applies to women desiring pregnancy 
(Shapiro, et al., 2011, Stevenson, et al., 2005).  
C 
 74 
How should bone health be monitored in women with POI? 75 
It is important to consider bone health at diagnosis in POI, and during ongoing care. GPP 
Measurement of BMD at initial diagnosis of POI should be considered for all women, but 
especially when there are additional risk factors (Kanis, et al., 2013). 
C 
If BMD is normal and adequate systemic estrogen replacement is commenced, the value of 
repeated DEXA scan is low. 
GPP 
If a diagnosis of osteoporosis is made and estrogen replacement or other therapy initiated, 
BMD measurement should be repeated within 5 years. A decrease in BMD should prompt 
GPP 
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review of estrogen replacement therapy and of other potential factors. Review by a specialist 
in osteoporosis may be appropriate.  
 76 
What are the consequences of POI for the cardiovascular system?  77 
Women with POI are at increased risk of cardiovascular disease and should be advised of risk 
factors that they can modify through behavioural change (e.g. stopping smoking, taking regular 
weight-bearing exercise, healthy weight) (Atsma, et al., 2006, Baba, et al., 2010, Cooper and 
Sandler, 1998, de Kleijn, et al., 2002, Gallagher, et al., 2011, Hong, et al., 2007, Hu, et al., 1999, 
Jacobsen, et al., 2003, Jacobsen, et al., 2004, Jacobsen, et al., 1999, Lokkegaard, et al., 2006, 
Mondul, et al., 2005, Perk, et al., 2012, van der Schouw, et al., 1996). 
B 
All women diagnosed with Turner Syndrome should be evaluated by a cardiologist with 
expertise in congenital heart disease (Bondy, 2008, Gravholt, et al., 1998, Sharma, et al., 2009).  
C 
 78 
Is estrogen replacement cardio-protective? 79 
Despite lack of longitudinal outcome data, hormone replacement therapy with early initiation 
is strongly recommended in women with POI to control future risk of cardiovascular disease; it 
should be continued at least until the average age of natural menopause (Kalantaridou, et al., 
2004, Langrish, et al., 2009, Lokkegaard, et al., 2006, Ostberg, et al., 2007). 
C 
 80 
Should cardiovascular risk factors be monitored?  81 
Page 17 of 43
http://humrep.oupjournals.org
Draft Manuscript Submitted to Human Reproduction for Peer Review
17 
 
Cardiovascular risk should be assessed in women diagnosed with POI. At least blood pressure, 
weight and smoking status should be monitored annually with other risk factors being 
assessed if indicated. 
GPP 
In women with Turner Syndrome, cardiovascular risk factors should be assessed at diagnosis 
and annually monitored (at least blood pressure, smoking, weight, lipid profile, fasting plasma 
glucose, HbA1c) (Freriks, et al., 2011).  
C 
 82 
What are the consequences of POI on psychological wellbeing and quality of life?  83 
A diagnosis of POI has a significant negative impact on psychological wellbeing and quality of 
life (Liao, et al., 2000, Mann, et al., 2012, Schmidt, et al., 2011). 
D 
 84 
What are the Management options for reduced quality of life associated with POI?  85 
Psychological and lifestyle interventions should be accessible to women with POI (Boivin, 2003, 
Duijts, et al., 2012, Mann, et al., 2012). 
B 
 86 
What are the consequences of POI for sexuality?  87 
Routinely inquire about sexual wellbeing and sexual function in women with POI. GPP 
 88 
What are the management options for the effects of POI on sexuality?  89 
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Adequate estrogen replacement is regarded as a starting point for normalising sexual function. 
Local estrogen may be required to treat dyspareunia (Pacello, et al., 2013, Rubinow, et al., 
1998, Sarrel, 1987). 
C 
Women with POI should receive adequate counselling about the possibility of using 
testosterone supplementation so that they can make an informed choice, in the knowledge 
that long-term efficacy and safety are unknown (Alexander, et al., 2004, Kingsberg, et al., 
2008).  
B 
 90 
What treatments are available for genito-urinary symptoms in POI?  91 
Local estrogens are effective in treatment of genito-urinary symptoms (Suckling, et al., 2006). A 
Clinicians should be aware that despite seemingly adequate systemic HRT, women with POI 
may experience genito-urinary symptoms. Local estrogens may be given in addition to 
systemic HRT (Pacello, et al., 2013).  
D 
Lubricants are useful for treatment of vaginal discomfort and dyspareunia for women not 
using HRT (Grimaldi, et al., 2012, Le Donne, et al., 2011). 
C 
 92 
What are the consequences of POI on neurological function?  93 
The possible detrimental effect on cognition should be discussed when planning hysterectomy 
and/or oophorectomy under the age of 50 years, especially for prophylactic reasons (Bove, et 
al., 2014, Phung, et al., 2010, Rocca, et al., 2007, Rocca, et al., 2008, Vearncombe and Pachana, 
2009).  
D 
 94 
What are the management options for the effect of POI on neurological function?  95 
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Estrogen replacement to reduce the possible risk of cognitive impairment should be 
considered in women with POI at least until the average age of natural menopause (Bove, et 
al., 2014, File, et al., 2002, Hogervorst and Bandelow, 2010, Kritz-Silverstein and Barrett-
Connor, 2002, Phillips and Sherwin, 1992, Sherwin, 1988, Sherwin, 1994).  
C 
Women with POI should be advised to take lifestyle measures (e.g. exercise, cessation of 
smoking, maintaining a healthy weight) to reduce possible risks for cognitive impairment. 
GPP 
 96 
TREATMENT 97 
Indications for hormone replacement therapy (HRT) 98 
Hormone replacement therapy is indicated for the treatment of symptoms of low estrogen in 
women with POI (Absolom, et al., 2008, Madalinska, et al., 2006, Piccioni, et al., 2004). 
C 
 Women should be advised that HRT may have a role in primary prevention of diseases of the 
cardiovascular system and for bone protection (Kalantaridou, et al., 2004, Kanis, et al., 2013, 
Langrish, et al., 2009, Lindsay, et al., 1980, Lokkegaard, et al., 2006, Ostberg, et al., 2007, Prior, 
et al., 1997). 
C 
 99 
What are the risks of hormone replacement therapy?  100 
Women with POI should be informed that HRT has not been found to increase the risk of 
breast cancer before the age of natural menopause (Benetti-Pinto, et al., 2008, Soares, et al., 
2010, Wu, et al., 2014). 
D 
Progestogen should be given in combination with estrogen therapy to protect the 
endometrium in women with an intact uterus (Furness, et al., 2012). 
B 
 101 
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What are the options for hormone replacement therapy?  102 
17-β estradiol is preferred to ethinylestradiol or conjugated equine estrogens for estrogen 
replacement (Crofton, et al., 2010, Langrish, et al., 2009). 
C 
Women should be informed that whilst there may be advantages to micronized natural 
progesterone, the strongest evidence of endometrial protection is for oral cyclical combined 
treatment  
GPP 
 103 
Patient preference for route and method of administration of each component of HRT must be 
considered when prescribing, as should contraceptive needs. 
GPP 
 104 
Monitoring HRT 105 
Once established on therapy, women with POI using HRT should have a clinical review 
annually, paying particular attention to compliance.   
GPP 
No routine monitoring tests are required but may be prompted by specific symptoms or 
concerns. 
GPP 
 106 
Treatment with androgens 107 
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Women should be informed that androgen treatment is only supported by limited data, and 
that long-term health effects are not clear yet (Braunstein, et al., 2005, Buster, et al., 2005, 
Davis, et al., 2008, Davis, et al., 2006, Panay, et al., 2010, Shifren, et al., 2000, Simon, et al., 
2005, Tamimi, et al., 2006) 
C  
If androgen therapy is commenced, treatment effect should be evaluated after 3-6 months 
and should possibly be limited to 24 months. 
GPP  
 108 
HRT in POI women with special issues 109 
Women with Turner Syndrome 110 
Girls and women with POI due to Turner Syndrome should be offered HRT throughout the 
normal reproductive lifespan (Crofton, et al., 2010, Downey, et al., 1991, Elsheikh, et al., 2000, 
Gravholt, et al., 1998, Khastgir, et al., 2003, Kodama, et al., 2012, Mortensen, et al., 2009, 
Romans, et al., 1998, Ross, et al., 1998, Swillen, et al., 1993). 
C 
 111 
Women with POI and a BRCA gene mutation or after breast cancer 112 
HRT is generally contra-indicated in breast cancer survivors (Antoine, et al., 2007). B 
HRT is a treatment option for women carrying BRCA1/2 mutations but without personal 
history of breast cancer after prophylactic bilateral salpingo-oophorectomy (BSO) (Armstrong, 
et al., 2004, Madalinska, et al., 2006, Rebbeck, et al., 2005). 
C 
 113 
Women with POI and endometriosis 114 
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For women with endometriosis who required oophorectomy, combined estrogen/progestogen 
therapy can be effective for the treatment of vasomotor symptoms and may reduce the risk of 
disease reactivation (Dunselman, et al., 2014).   
C 
 115 
Women with POI and migraine 116 
Migraine should not be seen as a contraindication to HRT use by women with POI. GPP 
Consideration should be given to changing dose, route of administration or regimen if migraine 
worsens during HRT. 
GPP 
Transdermal delivery may be the lowest-risk route of administration of estrogen for migraine-
sufferers with aura (Nappi, et al., 2001). 
D 
 117 
Women with POI and hypertension 118 
Hypertension should not be considered a contraindication to HRT use by women with POI GPP 
In hypertensive women with POI, transdermal estradiol is the preferred method of delivery 
(Langrish, et al., 2009, White, 2007). 
C 
 119 
Women with POI and a history of prior venous thromboembolism (VTE)  120 
Women with POI and a history of prior venous thromboembolism (VTE) or thrombophilic 
disorder should be referred to a haematologist prior to commencing HRT. 
GPP 
Transdermal estradiol is the preferred route of delivery for women with POI at increased risk 
of VTE (Canonico, et al., 2008). 
B 
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Women with POI and obesity  122 
Transdermal estradiol is the preferred method of delivery for women with POI requiring HRT 
who are obese or overweight (Canonico, et al., 2006). 
C 
 123 
Women with POI and fibroids 124 
Fibroids are not a contraindication to HRT use by women with POI (Ang, et al., 2001, Ciarmela, 
et al., 2014). 
B 
 125 
What complementary treatments are available in POI? 126 
Women with POI should be advised of risk factors that they can modify through behavioural 
change (e.g. stopping smoking, taking regular weight-bearing exercise, healthy weight). 
GPP 
Women should be informed that for most alternative and complementary treatments 
evidence on efficacy is limited and data on safety are lacking (Rada, et al., 2010).  
B 
 127 
PUBERTY INDUCTION (see also table 3). 128 
How should puberty be induced? 129 
Puberty should be induced or progressed with 17β-estradiol, starting with low dose at the age 
of 12 with a gradual increase over 2 to 3 years (Reiter, et al., 2001, Stephure and Canadian 
Growth Hormone Advisory Committee, 2005, van Pareren, et al., 2003).  
C 
In cases of late diagnosis and for those girls in whom growth is not a concern, a modified 
regimen of estradiol can be considered (Davenport, 2008). 
D 
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Evidence for the optimum mode of administration (oral or transdermal) is inconclusive. 
Transdermal estradiol results in more physiological estrogen levels and is therefore preferred 
(Ankarberg-Lindgren, et al., 2001, Cisternino, et al., 1991, Illig, et al., 1990, Mauras, et al., 
2007, Nabhan, et al., 2009, Piippo, et al., 2004, Torres-Santiago, et al., 2013). 
B 
The oral contraceptive pill is contra-indicated for puberty induction (Bondy and Turner 
Syndrome Study Group, 2007, Davenport, 2010).  
D 
Begin cyclical progestogens after at least 2 years of estrogen or when breakthrough bleeding 
occurs (Bondy and Turner Syndrome Study Group, 2007, Furness, et al., 2012).  
C 
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Discussion 133 
The ESHRE guideline on the management of women with premature ovarian insufficiency comprises 95 134 
recommendations and 4 statements on the diagnosis, sequelae and treatment of premature ovarian 135 
insufficiency. The recommendations have been formulated by a multidisciplinary group of experts based on 136 
the best available evidence, and they have been reviewed by relevant stakeholders. Based on the assessment 137 
of the current literature on POI during the development of the guideline it is clear that evidence is limited. Of 138 
the 95 recommendations, 33 (34.7%) were based on expert opinion, and graded as a good practice point. Only 139 
15 of the 31 key questions were regarding treatment and management options, while the other questions 140 
dealt with diagnosis, monitoring and sequelae of POI. From the 61 recommendations on interventions (not 141 
including monitoring), 12 (19.7%) could be based on good quality evidence (level A or B), 35 (57.4%) were 142 
based on moderate quality evidence (C or D), and 14 (22.9%) were formulated as GPP.  143 
The lack of sufficient high quality evidence on the interventions available for women was the most significant 144 
limitation for the current guideline, and has led to a number of topics for future research: (1)  the accuracy of 145 
biochemical markers (e.g. FSH, AMH) in the diagnosis of POI, (2) long-term health outcomes of POI, examining 146 
contributory factors such as smoking, and the effect of long-term HRT (3) fertility treatment and associated 147 
obstetric risks in women with POI (4) lifetime risk of fracture in women with POI, and the impact of 148 
interventions (5) cardiovascular risk factors in women with POI (6) impact of POI on wellbeing and quality of 149 
life, including interventions (7) comparisons of the efficacy, patient’s satisfaction and side effects of the 150 
different options for HRT, and (8) the optimal approach for oncological POI patients.  151 
One of the options explored for the collection of long-term data is a POI registry, as suggested by Panay and 152 
colleagues (Panay and Fenton, 2012).    153 
Despite the limitations of guidelines in general, and the limitations in the evidence supporting the current 154 
guideline, the guideline group is confident that this document will help best practice in the management of 155 
women with POI. Efforts will be undertaken to ensure adequate dissemination and implementation of the 156 
guideline.  157 
 158 
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 Table 1 
Interpretation on the grades of recommendations (Vermeulen, et al., 2014)   
 
The grades of the recommendations is only based on the strength of the supporting evidence. In formulating 
strong or weak recommendations, the guideline group took the strength of the supporting evidence into 
account, but weight it against the benefits and harms, and the preferences of clinicians and patients.  
Grades of 
recommendations 
Supporting evidence 
A Meta-analysis, systematic review or multiple randomized controlled 
trials (RCTs) (high quality) 
B Meta-analysis, systematic review or multiple RCTs (moderate quality) 
Single RCT, large non-randomized trial, case-control or cohort studies 
(high quality)  
C Single RCT, large non-randomized trial, case-control or cohort studies 
(moderate quality) 
D Non-analytical studies, case reports or case series (high or moderate 
quality) 
GPP Expert opinion  
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Table 2 
Summary of diagnostic workup  
Test Implications  
Positive test Negative test 
Genetic/Chromosomal 
Karyotyping 
(for diagnosis of Turner syndrome) 
Refer to endocrinologist, 
cardiologist and geneticist 
a second analysis of the 
karyotype in epithelial cells (in 
case of high clinical suspicion) 
Test for Y-chromosomal 
material 
Discuss gonadectomy with the 
patient 
 
Fra-X Refer to geneticist  
Autosomal genetic testing
a
   
Antibodies
b
 
ACA/21OH antibodies Refer to endocrinologist Re-test in case of clinical signs 
or symptoms 
TPO-Ab Test TSH every year 
a
 not at present indicated in women with POI, unless there is evidence suggesting a specific mutation (e.g. BPES). 
b.
 POI of unknown cause or if an immune disorder is suspected. 
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Table 3 
Estrogen substitution therapy in adolescence (adapted from (Bondy and Turner Syndrome Study Group, 
2007)) 
Age Age-specific suggestions Preparation/dose/comments 
12 -13 years  If no spontaneous development and 
FSH elevated, start low dose estrogens 
17β-estradiol (E2) 
Transdermal: 6.25 µg/day
a
 E2 via patch 
Oral micronized E2: 5 µg/kg/day or 0.25 
mg/day 
12.5 - 15 years Gradually increase E2 dose at 6-12 
months interval over 2 - 3 years
b
 to 
adult dose 
Transdermal E2: 12.5, 25, 37.5, 50, 75, 
100µg/day. (Adult dose: 100-200 µg/day) 
Oral E2: 5, 7.5, 10, 15 µg/kg/day.  
(Adult dose:  2-4 mg/day) 
14 – 16 years Begin cyclic progestogen after 2 years 
of estrogen or when breakthrough 
bleeding occurs 
Oral micronized progesterone 100-200 
mg/day or dydrogesterone 5-10 mg/day 
during 12 – 14 days of the month
c
    
a 
the lowest dose commercially available E2 transdermal patches deliver 25 or 50 µg/day; it is not established 
whether various means of dose fractionation (e.g., administering 1/8, 1/6, 1/4 patch overnight or daily or 
administering whole patches for 7-10 days per month) are equivalent.  
b
 with concomitant GH therapy in Turner Syndrome, to achieve an optimal adult height the increase in E2 dose 
might be relatively slow; while in cases of late diagnosis and for those girls in whom growth is not a 
consideration, E2 may be started at somewhat higher doses and escalated more rapidly. 
c
 for prolonged treatment progesterone, dydrogesterone or medroxyprogesterone are preferred to other 
progestogens because of their less negative effect on lipid metabolism and less androgenic effects (Lobo, 1987). 
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